A Phase 2 interventional study of Abiraterone acetate and Prednisolone in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 33rd largest by enrollment, is one of 5 that started in 2011, is one of 59 in phase 2, and was the 23rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 34th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2011, is one of 20 in phase 2, and was the 27th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression following treatment with a docetaxel-containing chemotherapy.
This is an open-label (all people know the identity of the intervention), multicenter, single arm (only one treatment group) study to evaluate the efficacy and safety of abiraterone acetate in patients with mCRPC. The study will be divided into screening phase (up to 28 days before enrollment), treatment phase including treatment cycles (each cycle of treatment will be 28 days), and follow-up phase. Approximately 80 patients will be enrolled into this study. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram and vital signs as well as pharmacokinetic (what the body does to drug) assessments will be conducted in this study. Patients will continue to receive abiraterone acetate plus prednisolone until disease progression or occurrence of unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abiraterone acetate · Drug: Prednisolone
Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
Also known as: JNJ-212082
Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
Percentage of Participants With Prostate-specific Antigen (PSA) Response
The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.
Time frame: Baseline, Month 4
Overall Survival
Overall survival is defined as the time interval from the date of the first dose to the date of death due to any reason.
Time frame: Up to 3 Years
Time to PSA Progression
Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined in the protocol-specific PSAWG criteria. For participants who have achieved a greater than or equal to (\>=) 50% decrease from the baseline PSA, assessment of time to disease progression is when the PSA has increased 50% above the nadir and at a minimum of 5 nanogram/mililiter (ng/mL). For participants without a PSA decrease of this magnitude or without a decrease, the time for progression is calculated at the time a 25% increase from baseline PSA has been achieved.
Time frame: Up to 28 Months
Percentage of Participants With Objective Radiographic Response
Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: Up to 3 Years
Serum Testosterone
Median serum testosterone concentration was reported at baseline and End-of-Treatment visit.
Time frame: Baseline and End-of-Treatment Visit (up to approximately 3 years)
Dehydroepiandrosterone Sulfate (DHEA-S)
Median DHEA-S concentration was reported at baseline and End-of-Treatment visit.
Time frame: Baseline and End-of-Treatment Visit (up to approximately 3 years)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Up to 3 Years
| Milestone | Abiraterone Acetate |
|---|---|
| Started | 82 |
| Completed | 0 |
| Not completed | 82 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 19 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Physician decision | 13 |
| Withdrew: Other | 7 |
| Withdrew: Progressive disease | 32 |
| Withdrew: Noncompliance with study drug | 1 |
Overall survival is defined as the time interval from the date of the first dose to the date of death due to any reason.
| Days | Abiraterone Acetate and Prednisolone |
|---|---|
| Overall Survival | 538 (358.0 to 660.0) |
Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined in the protocol-specific PSAWG criteria. For participants who have achieved a greater than or equal to (\>=) 50% decrease from the baseline PSA, assessment of time to disease progression is when the PSA has increased 50% above the nadir and at a minimum of 5 nanogram/mililiter (ng/mL). For participants without a PSA decrease of this magnitude or without a decrease, the time for progression is calculated at the time a 25% increase from baseline PSA has been achieved.
| Days | Abiraterone Acetate and Prednisolone |
|---|---|
| Time to PSA Progression | 141 (112.0 to 170.0) |
Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| Percentage of participants | Abiraterone Acetate and Prednisolone |
|---|---|
| Percentage of Participants With Objective Radiographic Response | 6.1 |
Median serum testosterone concentration was reported at baseline and End-of-Treatment visit.
| nanomole per liter | Abiraterone Acetate and Prednisolone |
|---|---|
| Baseline | 1.210 (1.21 to 5.02) |
| End-of-Treatment Visit | 1.210 (1.21 to 1.79) |
Median DHEA-S concentration was reported at baseline and End-of-Treatment visit.
| micromole per liter | Abiraterone Acetate and Prednisolone |
|---|---|
| Baseline | 0.725 (0.08 to 6.28) |
| End-of-Treatment Visit | 0.080 (0.08 to 0.20) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Abiraterone Acetate and Prednisolone |
|---|---|
| AEs | 81 |
| SAEs | 40 |
The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.
| Percentage of participants | Abiraterone Acetate and Prednisolone |
|---|---|
| Percentage of Participants With Prostate-specific Antigen (PSA) Response | 42.7 |
Collected over Approximately 3 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone Acetate | — | 40/82 (48.8%) | 73/82 (89%) |
| Event | Abiraterone Acetate |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/82 |
| VomitingGastrointestinal disorders | 3/82 |
| AstheniaGeneral disorders | 3/82 |
| Bone painMusculoskeletal and connective tissue disorders | 3/82 |
| Abdominal painGastrointestinal disorders | 2/82 |
| NauseaGastrointestinal disorders | 2/82 |
| PyrexiaGeneral disorders | 2/82 |
| CellulitisInfections and infestations | 2/82 |
| Spinal compression fractureInjury, poisoning and procedural complications | 2/82 |
| Decreased appetiteMetabolism and nutrition disorders | 2/82 |
| Event | Abiraterone Acetate |
|---|---|
| Bone painMusculoskeletal and connective tissue disorders | 21/82 |
| Back painMusculoskeletal and connective tissue disorders | 19/82 |
| NauseaGastrointestinal disorders | 18/82 |
| HypokalaemiaMetabolism and nutrition disorders | 15/82 |
| HypertensionVascular disorders | 15/82 |
| ConstipationGastrointestinal disorders | 14/82 |
| VomitingGastrointestinal disorders | 14/82 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 13/82 |
| Oedema peripheralGeneral disorders | 12/82 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 12/82 |
| Age, Continuous(years) | Abiraterone Acetate |
|---|---|
| Mean | 71 ± 7.35 |
| Sex: Female, Male(Participants) | Abiraterone Acetate |
|---|---|
| Female | 0 |
| Male | 82 |
| Region of Enrollment(Participants) | Abiraterone Acetate |
|---|---|
| Korea, Republic Of | 52 |
| Taiwan, Province Of China | 30 |
Ran from Aug 2011 to primary completion in Jan 2013, 16 months.
Results were first posted in May 2016, 3 years 3 months after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 16 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abiraterone Acetate · Prednisolone
Janssen Research & Development, LLC →